L

LatchBio

Cloud-based data platform for biotech R&D

AI Biologist - Medical Countermeasures

Quantitative Biology & BiostatisticsUpdated on Nov 14
Full-timeSan Francisco, CA, USA$140k - $180k /yr

About the Job

Requirements

  • At least 3 years of hands-on experience in vaccine or antibody development or antiviral development, ideally involving respiratory viruses such as influenza, RSV, or coronaviruses.
  • Deep expertise in at least one vaccine-and-antibody or antiviral area: vaccine antigen design, immunogen engineering, or therapeutic antibody discovery; epitope mapping, neutralization, cross-reactivity, and immune recognition; comparative evaluation of vaccine or antibody candidates using experimental data; antibody responses, immune imprinting, or waning immunity; antiviral susceptibility and resistance using phenotypic drug-response and viral sequence data; antiviral discovery, mechanism-of-action studies, or experimental candidate evaluation; treatment-emergent resistance, cross-resistance, and resistance-marker interpretation; or antiviral assay development, validation, and dose-response analysis.
  • A PhD in immunology, virology, microbiology, or a related field, or equivalent industry experience.
  • Hands-on experience analyzing the data rather than only supervising its analysis.
  • Daily use of Claude, ChatGPT, or similar AI tools, with the judgment to identify technically correct but scientifically wrong answers.
  • Confidence to overrule an AI agent and openness to updating conclusions when shown to be wrong.

Responsibilities

  • Convert real countermeasure workflows into tasks with clear, gradable answers, including antigen and immunogen comparison, epitope mapping, neutralization and cross-reactivity, antiviral susceptibility, and resistance interpretation.
  • Write gold-standard answers from raw data, with tolerances that reflect assay, replicate, and strain variability.
  • Curate neutralization titers, binding and epitope maps, serology time courses, EC50 and dose-response curves, and viral sequences with resistance markers.
  • Test whether agents distinguish genuine escape or resistance from artifacts, including assay drift, passenger mutations misidentified as resistance markers, and fold-changes unsupported by sequence data.
  • Test whether agents distinguish binding from neutralization, immunogenicity from protection, and laboratory resistance from clinical relevance.
  • Test whether agents account for immune imprinting, waning, and cross-resistance when ranking candidates.
  • Challenge conclusions that sound plausible but would not withstand a program review.
  • Identify where agents make errors, what an expert would do instead, and what evidence would change the assessment.
  • Reward explicit uncertainty rather than confident guesses.

About the Company

LatchBio

Cloud-based data platform for biotech R&D

Latch.bio provides a cloud-based data platform for biotech companies to manage and analyze their data. It stores unlimited raw data, organizes and transforms it, and offers analysis tools, all in one place. The platform also includes workflow orchestration, so teams can set up analyses that automatically run across many computing cores and scale as needed, while the interface makes it easy to view analysis results and make quick decisions. A key feature is a customizable data platform that eliminates the need for separate infrastructure setup and supports strong security for large-scale data processing. Compared with competitors, Latch.bio positions itself as a single, cost-efficient solution that replaces multiple tools and optimizes cloud usage to reduce expenses. Its goal is to help biotech companies move projects forward faster by making data analysis cheaper, simpler, and more accessible.

Company size
51-200
Company stage
Series B
Total funding
$163M
Headquarters
San Francisco, CA
Founded
2021

Recently Posted Jobs

Explore more opportunities at LatchBio

See more jobs